VICTORIA GASPARYAN: Open Payments
NPI 1912268004 · EDMONDS, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$447 in 18 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $708 · 2025 $447
Food & beverage: $447
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $118 |
| Braintree Laboratories, Inc. | 3 | $57 |
| Madrigal Pharmaceuticals | 2 | $53 |
| GENZYME CORPORATION | 1 | $45 |
| Phathom Pharmaceuticals, Inc. | 2 | $37 |
| Gilead Sciences, Inc. | 1 | $32 |
| Celltrion USA Inc. | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Lilly USA, LLC | 1 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
Products named: REZDIFFRA, SKYRIZI, DUPIXENT, VOQUEZNA, CREON, RINVOQ, SUTAB, VEGZELMA.
Industry payments across WA — which companies pay providers there.
